Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Fogelman DR; Wolff RA; Kopetz S; Javle M; Bradley C; Mok I; Cabanillas F; Abbruzzese JL

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

【24h】

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

机译：PARP-1抑制剂Iniparib在BRCA2相关的胰腺癌中疗效的证据。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a BRCA2 mutation. Breast and ovarian carcinomas that harbor BRCA2 mutations are susceptible to the effects of an emerging class of targeted agents, namely, poly(ADP-ribose) polymerase (PARP) inhibitors. This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer.

机译：胰腺癌是一种恶性肿瘤，通常是致命的恶性肿瘤，在美国每年袭击37,000名患者。它对吉西他滨等标准化学疗法的反应较差。大约5-10％的胰腺癌发生在BRCA2突变的背景下。具有BRCA2突变的乳腺癌和卵巢癌易受新兴靶向药物（聚（ADP-核糖）聚合酶（PARP）抑制剂）的影响。该报告描述了一个具有BRCA2生殖系突变和PARP抑制剂iniparib（BSI-201）治疗的相关胰腺癌的病例，该患者表现出对该药的完全病理反应。该病例强调了BRCA2相关胰腺癌中PARP抑制的潜在益处。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2011年第4期|共4页
作者
Fogelman DR; Wolff RA; Kopetz S; Javle M; Bradley C; Mok I; Cabanillas F; Abbruzzese JL;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. [J] . Fogelman DR, Wolff RA, Kopetz S, Anticancer Research: International Journal of Cancer Research and Treatment . 2011,第4期

机译：PARP-1抑制剂Iniparib在BRCA2相关的胰腺癌中疗效的证据。
2. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. [J] . Liang H, Tan AR IDrugs: the investigational drugs journal . 2010,第9期

机译：Iniparib，一种PARP1抑制剂，可潜在治疗癌症，包括三阴性乳腺癌。
3. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673 [J] . Andrei Alexandra-Zoe, Hall Anita, Smith Alyssa L., Cancer letters . 2015,第1期

机译：增加BRCA2相关胰腺癌对聚（ADP-核糖）聚合酶-1/2抑制剂BMN 673的体外和体内敏感性
4. 3D ultrasonic molecular imaging to assess the efficacy of an aurora kinase inhibitor in pancreatic adenocarcinoma [C] . Streeter Jason E., Herrera Gabriela, Cao Joey, 2011 IEEE International Ultrasonics Symposium . 2011

机译：3D超声分子成像可评估极光激酶抑制剂在胰腺腺癌中的疗效
5. Inhibitor of apoptosis proteins and associated factors in pancreatic cancer. [D] . Bastien, Jacynthe. 2005

机译：胰腺癌中凋亡蛋白及其相关因子的抑制剂。
6. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer [O] . George Somlo, Paul H. Frankel, Banu K. Arun, -1

机译：PARP抑制剂维利帕利布与卡铂或作为单一药物在生殖细胞BRCA1或BRCA2相关的转移性乳腺癌患者中的疗效
7. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. [O] . Yufeng Wang, Yasuhiro Kuramitsu, Kazuhiro Tokuda, 2014

机译：吉西他滨通过胰腺癌中的自噬诱导聚（aDp-核糖）聚合酶-1（paRp-1）降解。

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

摘要

著录项

相似文献

相关主题

期刊订阅